UA127502C2 - Кристалічні форми n-(4-(4-(циклопропілметил)піперазин-1-карбоніл)феніл)хінолін-8-сульфонаміду - Google Patents

Кристалічні форми n-(4-(4-(циклопропілметил)піперазин-1-карбоніл)феніл)хінолін-8-сульфонаміду Download PDF

Info

Publication number
UA127502C2
UA127502C2 UAA202003680A UAA202003680A UA127502C2 UA 127502 C2 UA127502 C2 UA 127502C2 UA A202003680 A UAA202003680 A UA A202003680A UA A202003680 A UAA202003680 A UA A202003680A UA 127502 C2 UA127502 C2 UA 127502C2
Authority
UA
Ukraine
Prior art keywords
crystalline form
compound
crystalline
subject
certain embodiments
Prior art date
Application number
UAA202003680A
Other languages
English (en)
Ukrainian (uk)
Inventor
Джейкоб П. Сайзмор
Літін Ґо
Литин Го
Магмуд Мірмеграбі
Магмуд Мирмеграби
Йєцин Су
Йецин Су
Original Assignee
Аджіос Фармасьютикалз, Інк.
Аджиос Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA127502(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аджіос Фармасьютикалз, Інк., Аджиос Фармасьютикалз, Инк. filed Critical Аджіос Фармасьютикалз, Інк.
Publication of UA127502C2 publication Critical patent/UA127502C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UAA202003680A 2017-11-22 2018-11-21 Кристалічні форми n-(4-(4-(циклопропілметил)піперазин-1-карбоніл)феніл)хінолін-8-сульфонаміду UA127502C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (1)

Publication Number Publication Date
UA127502C2 true UA127502C2 (uk) 2023-09-13

Family

ID=64734113

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA202003680A UA127502C2 (uk) 2017-11-22 2018-11-21 Кристалічні форми n-(4-(4-(циклопропілметил)піперазин-1-карбоніл)феніл)хінолін-8-сульфонаміду

Country Status (27)

Country Link
US (3) US11254652B2 (enExample)
EP (2) EP4285904A3 (enExample)
JP (2) JP7275130B2 (enExample)
KR (3) KR102682430B1 (enExample)
CN (2) CN117551030A (enExample)
AU (3) AU2018373122B2 (enExample)
BR (1) BR112020010185A2 (enExample)
CA (1) CA3081945A1 (enExample)
DK (1) DK3713919T3 (enExample)
ES (1) ES2959764T3 (enExample)
FI (1) FI3713919T3 (enExample)
HR (1) HRP20230931T1 (enExample)
HU (1) HUE063264T2 (enExample)
IL (3) IL274488B2 (enExample)
LT (1) LT3713919T (enExample)
MD (1) MD3713919T2 (enExample)
MX (2) MX2020005348A (enExample)
PH (1) PH12020550644A1 (enExample)
PL (1) PL3713919T3 (enExample)
PT (1) PT3713919T (enExample)
RS (1) RS64592B1 (enExample)
SG (1) SG11202004587XA (enExample)
SI (1) SI3713919T1 (enExample)
SM (1) SMT202300327T1 (enExample)
TW (2) TWI922809B (enExample)
UA (1) UA127502C2 (enExample)
WO (1) WO2019104134A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
JP2022533227A (ja) * 2019-05-22 2022-07-21 アジオス ファーマシューティカルズ， インコーポレイテッド Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性塩形態
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
US12286404B2 (en) * 2020-01-28 2025-04-29 Teva Pharmaceuticals International Gmbh Solid state forms of Mitapivat and process for preparation thereof
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
CA3196829A1 (en) * 2020-09-25 2022-03-31 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4329758A1 (en) 2021-04-30 2024-03-06 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2023154036A1 (en) * 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
KR20240107326A (ko) 2021-11-16 2024-07-09 아지오스 파마슈티컬스 아이엔씨. Mds 관련 빈혈 및 기타 상태를 치료하기 위한 화합물
US20260146025A1 (en) 2022-10-17 2026-05-28 Tianish Laboratories Private Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000510866A (ja) 1996-05-20 2000-08-22 ダーウィン・ディスカバリー・リミテッド Ｔｎｆとｐｄｅ―ｉｖのインヒビターとしてのキノリンスルホンアミド
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
US20010041706A1 (en) 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
AU2001288690A1 (en) 2000-09-05 2002-03-22 Odyssey Pharmaceuticals Llc Two-component anti-emetic composition comprising dexamethasone and metoclopramide
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
PE20120693A1 (es) * 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
US20140162942A1 (en) 2010-07-30 2014-06-12 Anima Ghosal Inhibition of cyp3a drug metabolism
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
US20140249150A1 (en) * 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
EP2877214B1 (en) * 2012-07-26 2019-04-24 Joslin Diabetes Center, Inc. Predicting diabetic complications
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
JP2017513921A (ja) 2014-03-03 2017-06-01 アーチャルジー、スジャータ ジストロフィン異常症を治療するためのキメラジストロフィン−ｖｓｖ−ｇタンパク質
MX384883B (es) * 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
KR102682430B1 (ko) 2017-11-22 2024-07-08 아지오스 파마슈티컬스 아이엔씨. N-(4-(4-(시클로프로필메틸)피페라진-1-카르보닐)페닐)퀴놀린-8-술폰아미드의 결정 형태
US11878049B1 (en) 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450

Also Published As

Publication number Publication date
AU2018373122B2 (en) 2023-11-09
EP3713919B1 (en) 2023-08-02
TWI922809B (zh) 2026-04-21
AU2018373122A1 (en) 2020-05-21
DK3713919T3 (da) 2023-09-25
KR20240108581A (ko) 2024-07-09
EP4285904A2 (en) 2023-12-06
CA3081945A1 (en) 2019-05-31
IL274488B2 (en) 2024-01-01
SG11202004587XA (en) 2020-06-29
IL274488B1 (en) 2023-09-01
KR20200090787A (ko) 2020-07-29
FI3713919T3 (fi) 2023-09-29
JP2023093762A (ja) 2023-07-04
US20200277279A1 (en) 2020-09-03
TWI808108B (zh) 2023-07-11
MD3713919T2 (ro) 2024-02-29
TW202334115A (zh) 2023-09-01
MX2020005348A (es) 2020-08-13
ES2959764T3 (es) 2024-02-28
KR20250034202A (ko) 2025-03-10
IL305343A (en) 2023-10-01
LT3713919T (lt) 2023-10-10
SMT202300327T1 (it) 2023-11-13
KR102777452B1 (ko) 2025-03-10
EP4285904A3 (en) 2023-12-20
US20220220093A1 (en) 2022-07-14
US20260217676A1 (en) 2026-07-30
IL305343B2 (en) 2026-01-01
RS64592B1 (sr) 2023-10-31
CN111372920A (zh) 2020-07-03
US11254652B2 (en) 2022-02-22
MX2022009998A (es) 2022-09-19
AU2024200724A1 (en) 2024-02-22
TW201930289A (zh) 2019-08-01
JP2021504338A (ja) 2021-02-15
IL322576A (en) 2025-10-01
BR112020010185A2 (pt) 2021-01-12
EP3713919A1 (en) 2020-09-30
WO2019104134A1 (en) 2019-05-31
JP7275130B2 (ja) 2023-05-17
PT3713919T (pt) 2023-10-26
PL3713919T3 (pl) 2023-12-27
US12612381B2 (en) 2026-04-28
AU2024200724B2 (en) 2026-02-05
AU2026203244A1 (en) 2026-05-14
IL305343B1 (en) 2025-09-01
CN117551030A (zh) 2024-02-13
KR102682430B1 (ko) 2024-07-08
CN111372920B (zh) 2023-10-20
SI3713919T1 (sl) 2023-10-30
HRP20230931T1 (hr) 2023-11-24
HUE063264T2 (hu) 2024-01-28
IL274488A (en) 2020-06-30
PH12020550644A1 (en) 2021-04-26

Similar Documents

Publication Publication Date Title
TWI808108B (zh) N-(4-(4-(環丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺醯胺之結晶型
TWI912383B (zh) 醫藥化合物之結晶形式、其製備方法、包含其之組合物及其用途
UA124433C2 (uk) Піридиноїлпіперидин, його застосування для лікування мігрені та фармацевтична композиція на його основі
KR20260010418A (ko) 2-((1h-피라졸-3-일)메틸)-6-((6-아미노피리딘-2-일)메틸)-4-메틸-4,6-디하이드로-5h-티아졸로[5',4':4,5]피롤로[2,3-d]피리다진-5-온의결정질 염 또는 비정질 형태
CN114026071B (zh) N-(4-(4-(环丙基甲基)哌嗪-1-羰基)苯基)喹啉-8-磺酰胺的结晶盐形式
EP0944612B1 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate
HK40104405A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
CN112770731A (zh) 以4’-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
NZ759132A (en) Solid forms of { [5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid, compositions, and uses thereof